Understanding Progression: How to Identify and Treat ESR1 Mutations in HR+ MBC

Register Here

New therapeutic options are now available for HR+ MBC. Dr. Virginia Kaklamani will discuss endocrine therapy resistance, liquid biopsy/blood test, mutations, and treatment sequencing of targeted therapy. You will learn about oral selective estrogen receptor degraders (SERDS), clinical trials, and more. Join us to hear the latest options and have your questions answered in this webinar.

Dr. Virginia Kaklamani, Professor of Medicine in the Division of Hematology/Oncology at the University of Texas Health Sciences Center in San Antonio and is the Leader of the Breast Cancer Program at the Mays Cancer Center UT Health San Antonio, MD Anderson Cancer Center


Thursday, 6-7pm ET
Oct 26

Register Here

National Helpline: